Arcus_JPM-2025-Presentation_FINAL.pdf

《Arcus_JPM-2025-Presentation_FINAL.pdf》由会员分享，可在线阅读，更多相关《Arcus_JPM-2025-Presentation_FINAL.pdf（19页珍藏版）》请在三个皮匠报告上搜索。

1、COMBINING TO CUREArcus is at the forefront of designing combination therapies,with best-in-class potential,in the relentless pursuit of cures for cancer.January 14,2025CORPORATE PRESENTATION Arcus Biosciences 2025Forward Looking Statements Safe Harbor:This presentation contains forward-looking state

2、ments about Arcus Biosciences,Inc.(“we,”“Arcus”or the“Company”)made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.All statements regarding events or results to occur in the future contained in this presentation are forward-looking statements,including

3、 statements about:our strategy,advantages,and expectations,including regarding our productivity and competitiveness;expectation that our cash and investments are sufficient to fund operations into mid-2027;potential of our investigational products and portfolio,including our investigational products

4、 potential to be best or first in class;anticipated benefits of our collaborations with Gilead,Taiho and AstraZeneca;achievement and expected timing of clinical and developmental milestones,including the initiation of clinical trials and the timing of data readouts;the availability or presentation o

5、f clinical data;launch of our investigational products and such products becoming an available treatment;potential market size and patient population for any of our investigational products;and possible first to market advantage for any of our investigational products.These forward-looking statement

6、s are subject to a number of risks,uncertainties and assumptions that may cause actual results to differ materially from those contained in any forward-looking statements we may make,including,but not limited to:risks associated with preliminary or interim clinical data or preclinical data not being